EMA seeks comments on revised global GCP guideline
Updates encourage more efficient clinical trial design
Pharmaceutical companies in the European Union have been asked by the European Medicines Agency (EMA) to comment on revised good clinical practice (GCP) guidance released by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
The changes encourage more efficient clinical trial design, conduct, oversight, recording and reporting.